Araki Marito

Affiliation and department：

Research field (5)： Hematology and oncology , Cell biology , Molecular biology , Pharmaceuticals - health and biochemistry , Tumor biology

Research keywords (6)： MPL , JAK2 , calreticulin , thrombopoietin , cytokine receptor , myeloproliferative neoplasms

Research theme for competitive and other funds (17)：

2022 - 2025 変異型CALRを標的とした骨髄増殖性腫瘍治療法の開発
2022 - 2025 細胞の動的応答を制御する海洋天然物の探索
2021 - 2024 Elucidation of the mechanism of bone marrow fibrosis by focusing on the differences in tumorigenicity between mutant CALR types
2021 - 2024 骨髄増殖性腫瘍を引き起こす受容体成熟機構の解明
2021 - 2024 TKI治療抵抗性の慢性骨髄性白血病細胞に対する新規治療戦略の開発

Show all

Papers (82)：

Satoshi Yamazaki, Yo Mabuchi, Takaharu Kimura, Eriko Grace Suto, Daisuke Hisamatsu, Yuna Naraoka, Ayako Kondo, Yuzuki Azuma, Riko Kikuchi, Hidekazu Nishikii, et al. Activated mesenchymal stem/stromal cells promote myeloid cell differentiation via CCL2/CCR2 signaling. Stem cell reports. 2024
Chiho Furuya, Yoshinori Hashimoto, Soji Morishita, Tadaaki Inano, Tomonori Ochiai, Shuichi Shirane, Yoko Edahiro, Marito Araki, Miki Ando, Norio Komatsu. MPL gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan. Hematology (Amsterdam, Netherlands). 2023. 28. 1. 2229131-2229131
Chang Liu, Misa Imai, Yoko Edahiro, Shuichi Mano, Hiraku Takei, Mai Nudejima, Akira Kurose, Soji Morishita, Miki Ando, Satoshi Tsuneda, et al. Establishment of isogenic induced pluripotent stem cells with or without pathogenic mutation for understanding the pathogenesis of myeloproliferative neoplasms. Experimental Hematology. 2023. 118. 12-20
Phase 1 Clinical Trial of PPMX-T003, a Novel Human Monoclonal Antibody Specific for Transferrin Receptor 1, to Evaluate its Safety, Pharmacokinetics, and Pharmacodynamics. Clinical Pharmacology in Drug Development. 2022
Mathys Grapotte, Manu Saraswat, Chloé Bessière, Christophe Menichelli, Jordan A. Ramilowski, Jessica Severin, Yoshihide Hayashizaki, Masayoshi Itoh, Michihira Tagami, Mitsuyoshi Murata, et al. Author Correction: Discovery of widespread transcription initiation at microsatellites predictable by sequence-based deep neural network (Nature Communications, (2021), 12, 1, (3297), 10.1038/s41467-021-23143-7). Nature Communications. 2022. 13. 1

ｍore...

MISC (67)：

奥田真帆, 荒木真理人, de Marchi Federico, 森下総司, 今井美沙, 森洋輔, 堀野芽生, 落合友則, 白根脩一, 枝廣陽子, et al. 骨髄増殖性腫瘍におけるCREB3L1遺伝子の発現とその意義. Cytometry Research. 2021. 31. Suppl. 41-41
増渕菜弥, 荒木真理人, 小松則夫. 【慢性骨髄性白血病(CML)および骨髄増殖性腫瘍(MPN)診療の最近の進歩】MPNにおけるcalreticulin遺伝子変異の意義. 血液内科. 2021. 82. 3. 339-346
田中良和, 影山大夢, 辺ひろみ, 増渕菜弥, 中島寛也, 小野寺かこ, 大城拓未, 松井崇, 小寺義男, 小川智久, et al. 海洋天然物由来の新規生理活性タンパク質の構造機能解析. 日本生化学会大会(Web). 2021. 94th
辺浩美, 影山大夢, 中島寛弥, 小野寺かこ, 増渕菜弥, 大城拓未, 松井崇, 小寺義男, 小川智久, 平山真, et al. Marine sponge lectin reveals the mechanism of sugar-chain mediated activation of MPL. 日本血液学会学術集会抄録(Web). 2021. 83rd
荒木真理人. 【血小板の産生、数に関連した最新トピックス】分子シャペロンの遺伝子異常により引き起こされる血小板増多. 日本血栓止血学会誌. 2020. 31. 5. 491-497

ｍore...

Patents (5)：

切断型の変異型calreticulin検出による骨髄増殖性腫瘍の診断
リンパ節腫脹病変の評価方法
骨髄増殖性腫瘍予防又は治療薬のスクリーニング方法
急性白血病における分化誘導薬の診断薬
急性前骨髄球性白血病治療薬のスクリーニング方法

Books (1)：

骨髄線維症(MF)〜分子病態の解明から新規治療薬の開発まで〜
医薬ジャーナル社 2016

Lectures and oral presentations (17)：

Targeting calreticulin neoantigen for the treatment of myeloproliferative neoplasms
(2020)
Oncogenic activation of thrombopoietin receptor by mutant calreticulin on cell surface
(The 78th Annual Meeting of the Japanese Cancer Association 2019)
The molecular mechanism of development of myeloproliferative neoplasms by calreticulin mutation
(29th Annual Meeting of the Japan Cytometry Society 2019)
Homomultimerization of mutant calreticulin is required for MPL-binding and -activation
(The 80th Annual Meeting of the Japanese Society of Hematology 2018)
The molecular mechanism of cytokine receptor activation by mutant molecular chaperon
(The 77th Annual Meeting of the Japanese Cancer Association 2018)

ｍore...

Education (3)：

1997 - 2000 Osaka University Graduate School of Pharmaceutical Sciences (PhD)
1995 - 1997 Osaka University Graduate School of Science (M.S.)
1991 - 1995 Science University of Tokyo Faculty of Science (BA. Chemistry)

Professional career (1)：

薬学博士 (大阪大学大学院)

Work history (6)：

2021/10 - 現在 Juntendo University Graduate School of Medicine
2019/05 - 2021/09 Juntendo University Graduate School of Medcine Department of Transfusion Medicine and Stem Cell Regulation Senior Associate Professor
2011/05 - 2019/04 Juntendo University Graduate School of Medcine Department of Transfusion Medicine and Stem Cell Regulation Associate Professor
2007/05 - 2011/04 National University of Singapore Junior PI/Senior Scientist
2000/07 - 2007/05 Howard Hughes Medical Institute, Duke University Medical Center Postdoc

Show all

Awards (14)：

2019/11 - 公益財団法人武田科学振興財団医学系研究継続助成
2019/11 - 第56回ベルツ賞 2等賞(共同受賞)
2019/03 - The best of Leukemia 2018
2018/12 - 公益財団法人先進医薬研究振興財団血液医学研究助成
2016/12 - Blood 2016 Top 10 manuscript

Show all

Association Membership(s) (3)：

THE JAPANESE CANCER ASSOCIATION , THE JAPANESE SOCIETY OF HEMATOLOGY , JAPAN CYTOMETRY SOCIETY

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page